Evaluation of Retinal Amyloid Imaging Sensitivity and Specificity Alone and in Combination with Blood-based Biomarkers to Amyloid Status as Determined by PET and/or CSF in Normal, MCI and Early AD Patients

Grants and Contracts Details

StatusActive
Effective start/end date4/11/193/21/23

Funding

  • NeuroVision Imaging Incorporated: $2.00